logo

For the Inventor, By the Inventor

Osaka, Japan

Yasunori Aoyama

This inventor holds 11 USPTO granted patents and 1 published patent application and 6 EPO patents. Top assignees: Shionogi Company Limited, Viiv Healthcare Company, Glaxosmithkline LLC. Active years: 2012-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasunori Aoyama. Retrieved from https://idiyas.com/inventor/yasunori-aoyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 23(Granted Patents)


Location History:

  • Amagasaki, JP (2014)
  • Osaka, JP (2012 - 2017)

Company Filing History:

goldMedal11 out of 1,001 
 
Shionogi Company Limited
 patents
silverMedal8 out of 43 
 
Viiv Healthcare Company
 patents
bronzeMedal2 out of 358 
 
Glaxosmithkline LLC
 patents
where one patent can have more than one assignee

Years Active: 2012-2017

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 9707246 - Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents (2017-07-18),
2. 9133216 - (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10 (2015-09-15),
3. 9012650 - Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents (2015-04-21),
4. 8981129 - 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4 (2015-03-17),
5. 8940912 - 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid (2015-01-27),
6. 8765965 - 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7 (2014-07-01),
7. 8710249 - Maltol ether processes and intermediates (2014-04-29),
8. 8691823 - Prodrugs of (4aS, 13ar)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-9-11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1H-pyrido[1,2-a]pyrrolo[1',2′:3:4]imidazo[1,2-d]pyrazine-8-carboxamide and their use in the treatment of HIV infection (2014-04-08),
9. 8580967 - Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof (2013-11-12),
10. 8217034 - Chemical compounds (2012-07-10),
11. 8183372 - Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1',2′:3,4]imidazo[1,2-d]pyrazines (2012-05-22),

Title: Yasunori Aoyama: Innovator in HIV Treatment

Introduction

Yasunori Aoyama is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating viral infections, including HIV. With a total of 11 patents to his name, Aoyama's work has the potential to impact the lives of many individuals affected by these diseases.

Latest Patents

Aoyama's latest patents include innovative compounds such as substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides, which are designed as HIV agents. This invention focuses on a method for treating viral infections, particularly HIV, by administering specific compounds that have shown promise in therapeutic applications. Additionally, he has developed intermediates like (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione, which are crucial in the preparation of therapeutic agents for HIV treatment.

Career Highlights

Throughout his career, Aoyama has worked with notable companies such as Shionogi & Company Limited and ViiV Healthcare. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in antiviral therapies.

Collaborations

Some of Aoyama's coworkers include Brian Alvin Johns and Jason Gordon Weatherhead. Their collaborative efforts have further advanced the research and development of innovative treatments for viral infections.

Conclusion

Yasunori Aoyama's contributions to the field of medicinal chemistry, particularly in the development of HIV treatments, highlight his role as a significant inventor. His innovative patents and collaborations with leading companies and experts underscore the importance of his work in improving healthcare outcomes for individuals affected by viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…